Condition: Small Cell Lung Cancer (SCLC) · Large Cell Neuroendocrine Cancer (LCNEC) · Neuroendocrine Prostate Cancer (NEPC) · Sponsor: Phanes Therapeutics
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
This description comes directly from the study's public registry record.
Phanes Therapeutics · 858-766-0852 · clinical-trials@phanestx.com
Always discuss trial participation with your own doctor first.
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | Recruiting |
| Yale University Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Washington University School of Medicine (Siteman Cancer Center) | St Louis, Missouri, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Sarah Cannon Research Institute University of Oklahoma | Oklahoma City, Oklahoma, United States | Recruiting |
| Providence Portland Medical Center | Portland, Oregon, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05652686